

James A Reiffel

List of Publications by Citations

Source: <https://exaly.com/author-pdf/241578/james-a-reiffel-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144 papers	2,933 citations	26 h-index	52 g-index
160 ext. papers	3,735 ext. citations	4.3 avg, IF	5.43 L-index

#	Paper	IF	Citations
144	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1261-1274	27.4	472
143	Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2597-2604	15.1	291
142	Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 2363-72	27.4	154
141	Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study. <i>JAMA Cardiology</i> , 2017 , 2, 1120-1127	16.2	135
140	The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015 , 8, 1048-56	6.4	106
139	Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour Holter monitors for arrhythmia detection. <i>American Journal of Cardiology</i> , 2005 , 95, 1055-9	3	105
138	Antiarrhythmic effects of omega-3 fatty acids. <i>American Journal of Cardiology</i> , 2006 , 98, 50i-60i	3	101
137	Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 325-33	15.1	93
136	Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. <i>Circulation</i> , 2019 , 140, 1834-1850	16.7	93
135	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <i>American Heart Journal</i> , 2014 , 167, 735-42.e2	4.9	80
134	Importance of beta blockade in the therapy of serious ventricular arrhythmias. <i>American Journal of Cardiology</i> , 1998 , 82, 9I-19I	3	74
133	Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. <i>American Heart Journal</i> , 2013 , 165, 622-9	4.9	53
132	Atrial fibrillation and stroke: epidemiology. <i>American Journal of Medicine</i> , 2014 , 127, e15-6	2.4	50
131	Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. <i>Journal of the American Heart Association</i> , 2013 , 2, e000110	6	45
130	Drug choices in the treatment of atrial fibrillation. <i>American Journal of Cardiology</i> , 2000 , 85, 12D-19D	3	44
129	Drug-device interactions: clinical considerations. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1985 , 8, 369-73	1.6	39
128	Effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction: a clue to the mechanisms of the action of digitalis on the sinus node. <i>American Journal of Cardiology</i> , 1979 , 43, 983-9	3	39

127	Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). <i>American Journal of Cardiology</i> , 2010 , 105, 1122-9	3	38
126	Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. <i>American Journal of Cardiology</i> , 2000 , 85, 1151-3, A10	3	35
125	Time in the Therapeutic Range for Patients Taking Warfarin in Clinical Trials: Useful, but Also Misleading, Misused, and Overinterpreted. <i>Circulation</i> , 2017 , 135, 1475-1477	16.7	34
124	Patient factors associated with quality of life in atrial fibrillation. <i>American Heart Journal</i> , 2016 , 182, 1354-1359	4.3	32
123	Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. <i>American Heart Journal</i> , 2009 , 158, 163-169.e1-3	4.9	30
122	Effects of aging and gender on QT dispersion in an overtly healthy population. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000 , 23, 1121-6	1.6	30
121	Rationale and design of REVEAL AF: a prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. <i>American Heart Journal</i> , 2014 , 167, 22-7	4.9	29
120	Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). <i>American Journal of Cardiology</i> , 2010 , 105, 1130-4	3	28
119	Electrophysiological testing of sinus node function: diagnostic and prognostic application-including updated information from sinus node electrograms. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994 , 17, 349-65	1.6	27
118	Issues in the use of generic antiarrhythmic drugs. <i>Current Opinion in Cardiology</i> , 2001 , 16, 23-9	2.1	26
117	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005358	5.8	25
116	Rhythm management in atrial fibrillation--with a primary emphasis on pharmacological therapy: Part 1. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 590-602	1.6	25
115	Rhythm management in atrial fibrillation--with a primary emphasis on pharmacological therapy: Part 2. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 742-52	1.6	25
114	Optimum duration of transtelephonic ECG monitoring when used for transient symptomatic event detection. <i>Journal of Electrocardiology</i> , 1991 , 24, 165-8	1.4	25
113	Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring. <i>American Journal of Cardiology</i> , 1997 , 79, 1048-53	3	24
112	Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice. <i>American Journal of Cardiology</i> , 2000 , 85, 46D-52D	3	23
111	Impact of structural heart disease on the selection of class III antiarrhythmics for the prevention of atrial fibrillation and flutter. <i>American Heart Journal</i> , 1998 , 135, 551-6	4.9	23
110	Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. <i>JACC: Clinical Electrophysiology</i> , 2016 , 2, 221-229	4.6	22

109	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017 , 10,	6.4	19
108	Propensity Score Matching: The Devil is in the Details Where More May Be Hidden than You Know. <i>American Journal of Medicine</i> , 2020 , 133, 178-181	2.4	18
107	Rhythm management in atrial fibrillation—with a primary emphasis on pharmacologic therapy: Part 3. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1998 , 21, 1133-45	1.6	17
106	Antiarrhythmic drug therapy for atrial fibrillation: are the guidelines guiding clinical practice?. <i>Clinical Cardiology</i> , 2006 , 29, 97-102	3.3	15
105	Cardioversion for atrial fibrillation: treatment options and advances. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009 , 32, 1073-84	1.6	14
104	Is arterial stiffness a contributing factor to atrial fibrillation in patients with hypertension? A preliminary investigation. <i>American Journal of Hypertension</i> , 2004 , 17, 213-6	2.3	14
103	Cardiology patient page. The implantable cardioverter-defibrillator: patient perspective. <i>Circulation</i> , 2002 , 105, 1022-4	16.7	14
102	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. <i>Circulation</i> , 2018 , 138, 889-897	16.7	12
101	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. <i>Heart</i> , 2018 , 104, 1850-1858	5.1	12
100	New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond?. <i>American Heart Journal</i> , 2007 , 154, 824-9	4.9	12
99	Current status of direct recordings of the sinus node electrogram in man. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1983 , 6, 1143-50	1.6	12
98	Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2017 , 187, 156-169	4.9	10
97	Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. <i>American Journal of Cardiology</i> , 1998 , 82, 72N-81N	3	10
96	Atrial fibrillation: what have recent trials taught us regarding pharmacologic management of rate and rhythm control?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011 , 34, 247-59	1.6	9
95	A contemporary look at classic trials in atrial fibrillation: what do they really show and how might they apply to future therapies?. <i>American Journal of Cardiology</i> , 2008 , 102, 3H-11H	3	9
94	Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?. <i>Current Opinion in Cardiology</i> , 2004 , 19, 58-63	2.1	9
93	Atypical proarrhythmia with dofetilide: monomorphic VT and exercise-induced torsade de pointes. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2005 , 28, 877-9	1.6	9
92	The Utility of Ambulatory Electrocardiographic Monitoring for Detecting Silent Arrhythmias and Clarifying Symptom Mechanism in an Urban Elderly Population with Heart Failure and Hypertension: Clinical Implications. <i>Journal of Atrial Fibrillation</i> , 2010 , 3, 193	0.8	9

91	Propensity-Score Matching: Optimal, Adequate, or Incomplete?. <i>Journal of Atrial Fibrillation</i> , 2018 , 11, 2130	0.8	9
90	Optimum Risk Assessment for Stroke in Atrial Fibrillation: Should We Hold the Status Quo or Consider Magnitude Synergism and Left Atrial Appendage Anatomy?. <i>Arrhythmia and Electrophysiology Review</i> , 2017 , 6, 161-166	3.2	8
89	Drug therapy for atrial fibrillation: what will its role be in the era of increasing use of catheter ablation?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009 , 32, 108-18	1.6	8
88	Practical algorithms for pharmacologic management of the post myocardial infarction patient. <i>Clinical Cardiology</i> , 2005 , 28, 128-37	3.3	8
87	Frequency of serious arrhythmias detected with ambulatory cardiac telemetry. <i>American Journal of Cardiology</i> , 2010 , 105, 1313-6	3	8
86	Formulation substitution: a frequently overlooked variable in cardiovascular drug management. <i>Progress in Cardiovascular Diseases</i> , 2004 , 47, 3-10	8.5	8
85	Intravenous Amiodarone in the Management of Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1999 , 4, 199-204	2.6	8
84	The Conversion of Paroxysmal or Initial Onset Atrial Fibrillation with Oral Ranolazine: Implications for a New "Pill-In-Pocket" Approach in Structural Heart Disease. <i>Journal of Atrial Fibrillation</i> , 2010 , 2,	0.8	8
83	Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. <i>American Heart Journal</i> , 2020 , 219, 128-136	4.9	8
82	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. <i>JAMA Cardiology</i> , 2019 , 4, 756-764	16.2	7
81	Novel oral anticoagulants. <i>American Journal of Medicine</i> , 2014 , 127, e16-7	2.4	7
80	Does a Brugada pattern ECG precipitated by excessive-dose flecainide provide a diagnosis of a Brugada syndrome patient and/or contraindicate its use? A case study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2011 , 4, e47-51	6.4	7
79	Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005 , 10 Suppl 1, S45-58	2.6	7
78	Time dependent changes in duration of ventricular repolarization after AV node ablation: insights into the possible mechanism of postprocedural sudden death. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000 , 23, 1539-44	1.6	7
77	An important indirect drug interaction between dronedarone and warfarin that may be extrapolated to other drugs that can alter gastrointestinal function. <i>American Heart Journal</i> , 2011 , 161, e5; author reply e7	4.9	6
76	Rate Versus Rhythm Control Pharmacotherapy For Atrial Fibrillation: Where are We in 2008?. <i>Journal of Atrial Fibrillation</i> , 2008 , 1, 21	0.8	6
75	Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. <i>Journal of Atrial Fibrillation</i> , 2017 , 9, 1551	0.8	6
74	Emboic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). <i>American Journal of Cardiology</i> , 2018 , 122, 1677-1683	3	6

73	Time to Revisit the Time in the Therapeutic Range. <i>Journal of Atrial Fibrillation</i> , 2017 , 9, 1569	0.8	5
72	Antiarrhythmic drugs and devices for the management of ventricular tachyarrhythmia in ischemic heart disease. <i>American Journal of Cardiology</i> , 1998 , 82, 311-401	3	5
71	The duration of the sinus node depolarization on transvenous sinus node electrograms can identify sinus node dysfunction and can suggest its severity. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1989 , 12, 1746-56	1.6	5
70	Time in the Therapeutic Range (TTR): An Overly Simplified Conundrum. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2017 , 8, 2643-2646	1.1	5
69	Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. <i>Heart</i> , 2020 , 106, 358-364	5.1	4
68	Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). <i>American Journal of Cardiology</i> , 2019 , 124, 864-870	3.7	4
67	Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020 , 13, e007775	6.4	3
66	Detection of Previously Unrecognized (Subclinical) Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2020 , 127, 169-175	3	3
65	New versus traditional approaches to oral anticoagulation in patients with atrial fibrillation. <i>American Journal of Medicine</i> , 2014 , 127, e15	2.4	3
64	The Power of One: a Highly Detailed, Log-Based, Case Example that Clearly Demonstrates the Effective Use of Ranolazine For the Control of Progressive Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2010 , 3, 304	0.8	3
63	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 263-272	4.6	2
62	Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials. <i>Journal of Cardiovascular Electrophysiology</i> , 2020 , 31, 1022-1030	2.7	2
61	The Interaction Among Atrial Thromboembolism, Atrial Fibrillation, and Atrial Cardiomyopathy. <i>American Journal of Cardiology</i> , 2019 , 124, 1317	3	2
60	Asymptomatic atrial fibrillation: problems of management. <i>Chest</i> , 2001 , 119, 628-31	5.3	2
59	The Use of Ranolazine in the Management of Recurrent Atrial Fibrillation After Percutaneous Radiofrequency Ablation. <i>Journal of Atrial Fibrillation</i> , 2012 , 5, 562	0.8	2
58	The Link Between CHADS-VASc Score and Thromboembolic Risk in Patients Without Known Atrial Fibrillation: Are We Missing a Silent Culprit?. <i>Journal of Atrial Fibrillation</i> , 2020 , 12, 2303	0.8	2
57	Relation of Antecedent Symptoms to the Likelihood of Detecting Subclinical Atrial Fibrillation With Inserted Cardiac Monitors. <i>American Journal of Cardiology</i> , 2021 , 145, 64-68	3	2
56	Reader's Comments: Beyond Atrial Fibrillation Patterns as Contributors to Risk of Thromboembolism. <i>American Journal of Cardiology</i> , 2019 , 124, 166	3	1

55	Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008274	6	1
54	Biomarkers and their relationship to atrial fibrillation: mechanisms, prognosis and management. <i>Biomarkers in Medicine</i> , 2019 , 13, 1433-1438	2.3	1
53	Structural heart disease: its importance in association with antiarrhythmic drug therapy. <i>Clinical Cardiology</i> , 1994 , 17, 113-6	3.3	1
52	Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators. <i>Current Cardiology Reports</i> , 2007 , 9, 381-6	4.2	1
51	Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2001 , 6, 333-9	2.6	1
50	How do physicians determine when to perform an "on-drug" electrophysiology study for efficacy determination in patients with sustained ventricular tachyarrhythmias: a previously unaddressed variable that may affect efficacy rates. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995 , 18, 406-16	1.6	1
49	The Concept of "Burden" in Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2012 , 4, 400	0.8	1
48	QT Prolongation Following Ectopic Beats: Initial Data Regarding The Upper Limit Of Normal With Possible Implications For Antiarrhythmic Therapy And Concealed (Unexpressed) Long QT. <i>Journal of Atrial Fibrillation</i> , 2009 , 1, 113	0.8	1
47	TTR: Time in Therapeutic Range or "The Troublesome Report"?. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2019 , 10, 3469-3470	1.1	1
46	Risk of Major Bleeding in Patients With Atrial Fibrillation Taking Dronedronarone in Combination With a Direct Acting Oral Anticoagulant (From a U.S. Claims Database). <i>American Journal of Cardiology</i> , 2021 , 159, 79-86	3	1
45	Abstract 189: Identifying Patients at Highest Risk of Developing Atrial Fibrillation and the Role of Remote Prior Stroke: Insights From the REVEAL AF Study. <i>Stroke</i> , 2018 , 49,	6.7	1
44	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. <i>American Heart Journal</i> , 2020 , 220, 145-154	4.9	1
43	"Pill in the Pocket" Antiarrhythmic Drugs for Orally Administered Pharmacologic Cardioversion of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021 , 140, 55-61	3	1
42	The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios. <i>Reviews in Cardiovascular Medicine</i> , 2004 , 5 Suppl 5, S12-21	3.9	1
41	When Silence Isn't Golden: The Case of "Silent" Atrial Fibrillation. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2017 , 8, 2886-2893	1.1	0
40	Patterns of oral anticoagulation use with cardioversion in clinical practice. <i>Heart</i> , 2021 , 107, 642-649	5.1	0
39	Use of the HAVOC Score to Identify Patients at Highest Risk of Developing Atrial Fibrillation. <i>Cardiology</i> , 2021 , 146, 633-640	1.6	0
38	AIM-AF: A Physician Survey in the United States and Europe.. <i>Journal of the American Heart Association</i> , 2022 , e023838	6	0

37	Drug Interactions Affecting Antiarrhythmic Drug Use.. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022 , 101161CIRCEP121007955	6.4	o
36	Abnormal ECG, Seizures, and Associated Neurological Deficits. <i>Circulation</i> , 2017 , 135, 490-491	16.7	
35	To the Editor- Minimal QT, not just maximal, may underlie TdP risk in women. <i>Heart Rhythm</i> , 2017 , 14, e51	6.7	
34	The R-Wave Sign as a Predictor of Ventricular Tachyarrhythmias in Brugada Syndrome: The Criteria Need Verification and Clarification. <i>American Journal of Cardiology</i> , 2017 , 120, 2299	3	
33	The high road, the low road, and no road: She took them all. <i>Journal of Electrocardiology</i> , 2020 , 60, 175-176	1.4	
32	Sinus node depolarization - Present during all sinus rhythms but never seen on the 12-lead ECG: An illustrative case-report that provides its recording. <i>Journal of Electrocardiology</i> , 2020 , 60, 192-194	1.4	
31	QT Interval Abnormalities with Pulmonary Emboli. <i>American Journal of Medicine</i> , 2020 , 133, e113	2.4	
30	An Incomplete Story. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 104	15.1	
29	Letter by Reiffel Regarding Article, "Treatment of Subclinical Atrial Fibrillation: Does One Plus One Always Equal Two?". <i>Circulation</i> , 2018 , 138, 122-123	16.7	
28	When an Omission Alters the Message, Missing Facts Must be Added. <i>American Journal of Medicine</i> , 2019 , 132, e722	2.4	
27	Selective Reporting: Silent Atrial Fibrillation and Cryptogenic Strokes. <i>American Journal of Medicine</i> , 2017 , 130, e403	2.4	
26	Chronic Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation Using Antiarrhythmic Drugs: Update 2010. <i>Cardiac Electrophysiology Clinics</i> , 2010 , 2, 409-418	1.4	
25	Role of Invasive EP Testing in the Evaluation and Management of Bradyarrhythmias/Sinus Node Dysfunction. <i>Journal of Interventional Cardiac Electrophysiology</i> , 1997 , 1, 414-416		
24	Demystifying the rate versus rhythm conundrum: new perspectives on recent trials and future treatment options. Introduction. <i>American Journal of Cardiology</i> , 2008 , 102, 1H-2H	3	
23	Clinical pearls in cardiovascular drug therapy: Class effects and individual drug features: Introductory comments. <i>Progress in Cardiovascular Diseases</i> , 2004 , 47, 1-2	8.5	
22	Have sanctioned algorithms replaced empiric judgment in the selection process of antiarrhythmic drugs for the therapy for atrial fibrillation?. <i>Current Cardiology Reports</i> , 2004 , 6, 365-70	4.2	
21	Microcomplex--a new incomplete heart block pattern. <i>Journal of Electrocardiology</i> , 2002 , 35, 273-8	1.4	
20	Clinical pearls in cardiovascular drug therapy: Class effects and individual drug featuresIntroductory comments. <i>Progress in Cardiovascular Diseases</i> , 2004 , 47, 1-2	8.5	

- 19 Role of Invasive EP Testing in the Evaluation and Management of Bradyarrhythmias/Sinus Node Dysfunction. *Journal of Interventional Cardiac Electrophysiology*, **2000**, 4, 17-19
- 18 The Duration of Induced Ventricular Tachycardia as Related to Clinically Sustained Ventricular Tachycardia. *Journal of Electrophysiology*, **1989**, 3, 127-134
- 17 The Relationship Between Sinoatrial Conduction Time and Sinus Cycle Length Revisited. *Journal of Cardiovascular Electrophysiology*, **1990**, 1, 290-299 2.7
- 16 Pharmacologic Management of Atrial Fibrillation and Flutter. *Contemporary Cardiology*, **2020**, 359-407 0.1
- 15 Electrophysiological Changes of the Atrium in Patients with Lone Paroxysmal Atrial Fibrillation. *Journal of Atrial Fibrillation*, **2010**, 3, 251 0.8
- 14 GIANT Flutter Waves in ECG Lead V1: a Marker of Pulmonary Hypertension. *Journal of Atrial Fibrillation*, **2008**, 1, 116 0.8
- 13 Dronedronedrone: Where Does it Fit in the AF Therapeutic Armamentarium?. *Journal of Atrial Fibrillation*, **2013**, 5, 752 0.8
- 12 The Anticoagulated Atrial Fibrillation Patient Who Requires "Curative" Therapy for Prostate Carcinoma: a Bleeding Conundrum. *Journal of Atrial Fibrillation*, **2008**, 1, 110 0.8
- 11 Considerations Regarding the Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. *Journal of Innovations in Cardiac Rhythm Management*, **2018**, 9, 3282-3283 1.1
- 10 Are we at the goal line with the novel oral anticoagulants and have we reached the end of the line for dronedronedrone and vernakalant--or is there more to come?. *Current Cardiology Reviews*, **2014**, 10, 315-6^{2.4}
- 9 Pharmacologic Management of Atrial Fibrillation and Flutter **2011**, 165-193
- 8 Could Different Thresholds for Tachycardic-Induced Atrial Myopathy Reflect Different Rates Between Atrial Fibrillation and Flutter?. *Journal of the American College of Cardiology*, **2020**, 76, 2179 15.1
- 7 When the time in the therapeutic range falls short: out of range values can be of importance. *European Heart Journal - Cardiovascular Pharmacotherapy*, **2021**, 7, e20 6.4
- 6 Letter by Reiffel Regarding Article, "Unique ECG During Sinus Rhythm in a Patient With A Postmyocardial Infarction-Sustained Ventricular Tachycardia". *Circulation*, **2018**, 138, 328-329 16.7
- 5 Letter by Reiffel Regarding Article, "Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative". *Circulation*, **2021**, 144, e160 16.7
- 4 Clinicians May Disagree About the Usefulness of the Physical Exam, but Those Who Refute It Are Wrong. *American Journal of Medicine*, **2021**, 134, e496 2.4
- 3 Selected Advancements in the Management of Atrial Fibrillation from the Year 2021.. *Journal of Innovations in Cardiac Rhythm Management*, **2022**, 13, 4840-4846 1.1
- 2 The safety of flecainide for atrial fibrillation in patients with stable coronary artery disease - Fact or fallacy.. *American Heart Journal*, **2022**, 248, 163-164 4.9

1

Guidelines Are Meant to Guide, But They Are Not Absolute. *American Journal of Medicine*, **2022**, 135, e132

2.4